Bharath Kumar Velmurugan1, Chun-Wen Chiu2, Yueh-Min Lin3,4,5, Mahalakshmi Bharath6, Chung-Min Yeh3,7, Yu-En Chen3, Chia-Min Chung8,9, Shu-Hui Lin10,5. 1. Department of Biotechnology, Asia University, Taichung, Taiwan, R.O.C. 2. Department of Emergency Medicine, Changhua Christian Hospital, Changhua, Taiwan, R.O.C. 3. Department of Surgical Pathology, Changhua Christian Hospital, Changhua, Taiwan, R.O.C. 4. School of Medicine, Chung Shan Medical University, Taichung, Taiwan, R.O.C. 5. Department of Medical Laboratory Science and Biotechnology, Central Taiwan University of Science and Technology, Taichung, Taiwan, R.O.C. 6. Institute of Research and Development, Duy Tan University, Da Nang, Vietnam. 7. Department of Medical Technology, Jen-Teh Junior College of Medicine, Nursing and Management, Miaoli, Taiwan, R.O.C. 8. Graduate Institute of BioMedical Sciences, China Medical University, Taichung, Taiwan, R.O.C. 9. Environment-Omics-Diseases Research Center, China Medical University Hospital, Taichung, Taiwan, R.O.C. 10. Department of Surgical Pathology, Changhua Christian Hospital, Changhua, Taiwan, R.O.C. 74630@cch.org.tw.
Abstract
BACKGROUND/AIM: Glycogen synthase kinase 3 beta (GSK3-β) acts either as a tumor suppressor or an oncogene in various human cancers. The present study aimed to investigate the expression and activity of p-GSK3-β (Ser9) in oral cancer patients. MATERIALS AND METHODS: We investigated the levels of p-GSK3β in 152 oral cancer tissues by immunohistochemistry, and explored their prognostic impact. RESULTS: To investigate the role of p-GSK3β (Ser9) in OSCC progression, we first analyzed the expression levels of protein p-GSK3β in normal and oral cancer tissues using immunohistochemical staining. p-GSK3β immunostaining was detected in 32 of 152 (21.1%) oral cancer specimens. High p-GSK3β expression was significantly associated with T (III/IV) stage. Kaplan-Meier survival analysis revealed that high levels of p-GSK3β were correlated with poor survival (p=0.001) in T stage (III/IV) OSCC patients. Multivariate analyses indicated that TN stage, AJCC tumor stage, tumor differentiation status and clinical therapy, but not p-GSK3β levels, were independent prognostic factors. Significant mortality risk was found in T stage (III/IV) oral cancer patients with high levels of p-GSK3β (p=0.0006). CONCLUSION: GSK3β inactivation is a key event in oral cancer patients and targeting GSK3β might be valuable in treating oral cancer patients. Copyright
BACKGROUND/AIM: Glycogen synthase kinase 3 beta (GSK3-β) acts either as a tumor suppressor or an oncogene in various humancancers. The present study aimed to investigate the expression and activity of p-GSK3-β (Ser9) in oral cancerpatients. MATERIALS AND METHODS: We investigated the levels of p-GSK3β in 152 oral cancer tissues by immunohistochemistry, and explored their prognostic impact. RESULTS: To investigate the role of p-GSK3β (Ser9) in OSCC progression, we first analyzed the expression levels of protein p-GSK3β in normal and oral cancer tissues using immunohistochemical staining. p-GSK3β immunostaining was detected in 32 of 152 (21.1%) oral cancer specimens. High p-GSK3β expression was significantly associated with T (III/IV) stage. Kaplan-Meier survival analysis revealed that high levels of p-GSK3β were correlated with poor survival (p=0.001) in T stage (III/IV) OSCC patients. Multivariate analyses indicated that TN stage, AJCC tumor stage, tumor differentiation status and clinical therapy, but not p-GSK3β levels, were independent prognostic factors. Significant mortality risk was found in T stage (III/IV) oral cancerpatients with high levels of p-GSK3β (p=0.0006). CONCLUSION: GSK3β inactivation is a key event in oral cancerpatients and targeting GSK3β might be valuable in treating oral cancerpatients. Copyright
Authors: Cuiling Ma; Jian Wang; Ying Gao; Tian-Wen Gao; Gang Chen; Kimberly A Bower; Mohammed Odetallah; Min Ding; Zunji Ke; Jia Luo Journal: Cancer Res Date: 2007-08-15 Impact factor: 12.701
Authors: Smitha R Georgy; Michael Cangkrama; Seema Srivastava; Darren Partridge; Alana Auden; Sebastian Dworkin; Catriona A McLean; Stephen M Jane; Charbel Darido Journal: J Natl Cancer Inst Date: 2015-06-10 Impact factor: 13.506